PEER-TO-PEER

PEER-TO-PEER

XPHOZAH EVENTS

Learn more about XPHOZAH from leading nephrologists

XPHOZAH National Broadcasts

Glenn M. Chertow, MD, MPH

Expert

Glenn M. Chertow, MD, MPH

Stanford University School of Medicine
Stanford, CA

Arnold Silva, MD

Expert

Arnold Silva, MD

Director of the Home Hemodialysis and Peritoneal Dialysis ProgramsBoise Kidney & Hypertension InstituteMeridian, Idaho

Image: Stuart M. Sprague, DO

Expert

Stuart M. Sprague, DO

Northshore University Health System and University of ChicagoChicago, IL

Image: Kevin J. Martin, MD, FASN, BRCU

Expert

Kevin J. Martin, MD, FASN, BRCU

St. Louis University School of Medicine
St. Louis, MO

David M. Spiegel, MD

Moderator

David M. Spiegel, MD

Vice President, Nephrology
Ardelyx, Inc.

Experts are paid advisors of Ardelyx, Inc.

There are multiple dates available.

Click below to register for the date that works for you.

RELATED LINKS

Mechanism of Action

Efficacy

Indication

XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Important Safety Information

Contraindications

XPHOZAH is contraindicated in:

  • Pediatric patients under 6 years of age
  • Patients with known or suspected mechanical gastrointestinal obstruction

Warnings and precautions

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

Most Common Adverse Reactions

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

For additional safety information, please see full Prescribing Information.

Indication

XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Important Safety Information

Contraindications

XPHOZAH is contraindicated in:

  • Pediatric patients under 6 years of age
  • Patients with known or suspected mechanical gastrointestinal obstruction

Warnings and precautions

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

Most Common Adverse Reactions

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

For additional safety information, please see full Prescribing Information.

Close

Connect with us for more information and continued updates about XPHOZAH.

Fill out the information below to register for updates.

*Required field.

Close

Close